Phagos raises €25 million Series A for AI-driven veterinary phage therapy

Paris-based Phagos has raised a €25 million Series A co-led by CapAgro, Hoxton Ventures, CapHorn and Demeter. The funds will go to deploying its veterinary phage treatments in the field, developing the next generation of its AI phage-discovery technology and expanding in Europe, Asia and the Americas; the company says it holds the first authorization to market personalized veterinary phage-based treatments in the EU.